Skip to main content

Advertisement

SpringerLink
Log in

The treatment of tics

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Tics are the essential component of a variety of disorders, notably Tourette syndrome. Because the mere presence of tics does not require therapeutic intervention, criteria are essential for determining a functional disability. Suggested tic-suppressing treatments have been extremely diverse, including hydrotherapy, behavioral treatments, pharmacotherapy, botulinum toxin, immunomodulatory therapy, and surgery. This manuscript reviews each of these approaches with emphasis on more recent pharmacologic trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tourette’s syndrome—tics, obsessions, compulsions. In Developmental Psychopathology and Clinical Care. Edited by Leckman JF, Cohen DJ. New York: John Wiley & Sons; 1999.

    Google Scholar 

  2. Jankovic J, ed.: Neurologic Clinics: In Tourette Syndrome. Philadelphia: WB Saunders; 1997.

    Google Scholar 

  3. Robertson MM: Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000, 123:425–462.

    Article  PubMed  Google Scholar 

  4. Singer HS: Tourette syndrome and its associated neurobehavioral problems. In Pediatric Neurology: Principles and Practice, edn 2. Edited by Swaiman K, Shields D. Baltimore, Mosby; 1999:598–605.

    Google Scholar 

  5. Singer HS: Current issues in Tourette syndrome. Mov Disord 2000, in press.

  6. Turpin G: The behavioral management of tic disorders: a critical review. Adv Behav Res Ther 1983, 5:203–245.

    Article  Google Scholar 

  7. Evers RA, van de Wetering BJ: A treatment model for motor tics based on a specific tension-reduction technique. J Behav Ther Exper Psychiatry 1994, 25:255–260.

    Article  CAS  Google Scholar 

  8. Ollendick TH: Self-monitoring and self-administered overcorrection: the modification of nervous tics in children. Behav Modification 1981, 5:75–84.

    Article  Google Scholar 

  9. Wright KM, Miltenberger RG: Awareness training in the treatment of head and facial tics. J Behav Ther Exper Psychiatry 1987, 18:269–274.

    Article  CAS  Google Scholar 

  10. Miltenberger RG, Fuqua RW, McKinley T: Habit reversal with muscle tics: replication and component analysis. Behav Therapy 1985, 16:39–50.

    Article  Google Scholar 

  11. Woods DW, Miltenberger RG, Lumley VA: Sequential application of major habit-reversal components to treat motor tics in children. J Appl Behav Analysis 1996, 29:483–493.

    Article  CAS  Google Scholar 

  12. Azrin NH, Peterson AL: Habit reversal for the treatment of Tourette syndrome. Behav Res Therapy 1988, 26:347–351.

    Article  CAS  Google Scholar 

  13. Bergin A, Waranch HR, Brown J, et al.: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998, 18:136–142.

    Article  PubMed  CAS  Google Scholar 

  14. Wu L, Li H, Kang L: 156 cases of Gilles de la Tourette’s syndrome treated by acupuncture. J Tradit Chin Med 1996, 16:211–213.

    PubMed  CAS  Google Scholar 

  15. Leckman JF, Detlor J, Harcherik DF, et al.: Short- and long-term treatment of Tourette’s syndrome with clonidine: a clinical perspective. Neurology 1985, 35:343–351.

    PubMed  CAS  Google Scholar 

  16. Leckman JF, Hardin MT, Riddle MA, et al.: Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1991, 48:324–328.

    PubMed  CAS  Google Scholar 

  17. Goetz CG, Tanner CM, Wilson RS, et al.: Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol 1987, 21:307–310.

    Article  PubMed  CAS  Google Scholar 

  18. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, et al.: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995, 34:1140–1146.

    Article  PubMed  CAS  Google Scholar 

  19. Cohn LM, Caliendo GC: Guanfacine use in children with attention deficit hyperactivity disorder [letter]. Ann Pharmacother 1997, 31:918–919.

    PubMed  CAS  Google Scholar 

  20. Shapiro AK, Shapiro ES, Young JG, Feinberg TE: Gilles de la Tourette syndrome, edn 2. New York: Raven Press; 1988.

    Google Scholar 

  21. Awaad Y: Tics in Tourette syndrome: new treatment options. J Child Neurol 1999, 14:316–319.

    PubMed  CAS  Google Scholar 

  22. Singer HS, Krieger M, Wendlandt JT, Giuliano J: Suppression of tics with baclofen: double-blind, placebo-controlled, crossover clinical trial. Ann Neurol 2000, 48:544–545. Important study.

    Google Scholar 

  23. Gonce M, Barbeau A: Seven cases of Gilles de la Tourette’s syndrome: partial relief with clonazepam. A pilot study. Can J Neurol Sci 1977, 3:279–283.

    Google Scholar 

  24. Steingard RJ, Goldberg M, Lee D, et al.: Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994, 33:394.

    Article  PubMed  CAS  Google Scholar 

  25. Drtilková I, Balaötková B, Lemanová H, Zák J: Therapeutical effects of clonidine and clonazepam in children with tic syndrome. Homeost Health Dis 1994, 35:296.

    Google Scholar 

  26. Lampreave JL, Molina V, Mardomingo MJ, et al.: Technetium-99m-HMPAO in Tourette’s syndrome on neuroleptic therapy and after withdrawal. J Nucl Med 1998, 39:624–628.

    PubMed  CAS  Google Scholar 

  27. Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989, 46:722–730.

    PubMed  CAS  Google Scholar 

  28. Sallee FR, Nesbitt L, Jackson C, et al.: Relative efficacy of haloperidol and pimozide in children with adolescents with Tourette disorder. Am J Psychiatry 1997, 8:1057–1062.

    Google Scholar 

  29. Tourette Syndrome Study Group: Short-term versus longer term pimozide therapy in Tourette’s syndrome: a preliminary study. Neurology 1999, 52:874–877. An interesting study.

    Google Scholar 

  30. Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci1986, 12:71–74.

    Google Scholar 

  31. Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271–272.

    PubMed  CAS  Google Scholar 

  32. Singer HS, Rabins P, Tune LE, Coyle JT: Serum haloperidol levels in Gilles de la Tourette syndrome. Biol Psychiatry 1981, 16:79–84.

    PubMed  CAS  Google Scholar 

  33. Lombroso PJ, Scahill L, King RA, et al.: Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995, 34:1147–1152.

    Article  PubMed  CAS  Google Scholar 

  34. Van der Linden C, Bruggeman R, Van Woerkom T: Serotonindopamine antagonist and Gilles de la Tourette’s syndrome: an open pilot dose-titration study with risperidone [letter]. Mov Disord 1994, 9:687–688.

    Article  PubMed  Google Scholar 

  35. Bruun RD, Budman CL: Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry 1996, 57:29–31.

    PubMed  CAS  Google Scholar 

  36. Robertson MM, Scull DA, Eapen V, Trimble MR: Risperidone in the treatment of Tourette syndrome: a retrospective case note study. J Psychopharmacol 1996, 10:317–320.

    Article  CAS  Google Scholar 

  37. Benji Semerci Z: Olanzapine in Tourette’s disorder. J Am Acad Child Adolesc Psychiatry 2000, 39:140.

    Article  Google Scholar 

  38. Onofrj M, Paci C, D’Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week doubleblind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443–446.

    Article  PubMed  CAS  Google Scholar 

  39. Stamenkovic M, Schnidler SD, Aschauer HN, et al.: Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin Psychopharmacol 2000, 15:23–28.

    PubMed  CAS  Google Scholar 

  40. Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292–299.

    Article  PubMed  CAS  Google Scholar 

  41. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH: The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979, 136:317–320.

    PubMed  CAS  Google Scholar 

  42. Schmider J, Hoff P: Clozapine in Tourette’s syndrome. J Clin Psychopharmacol 1998, 18:88–89.

    Article  PubMed  CAS  Google Scholar 

  43. Kalian M, Lerner V, Goldman M: Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J Nerv Ment Dis 1993, 181:649–651.

    Article  PubMed  CAS  Google Scholar 

  44. Jaffe E, Tremeau F, Sharif Z, Reider R: Clozapine in tardive Tourette syndrome. Biol Psychiatry 1995, 38:196–197.

    Article  PubMed  CAS  Google Scholar 

  45. Jankovic J, Glaze DG, Frost JD Jr: Effect of tetrabenazine on tics and sleep of Gilles de la Tourette’s syndrome. Neurology 1984, 34:688–692.

    PubMed  CAS  Google Scholar 

  46. Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358–362.

    PubMed  CAS  Google Scholar 

  47. Fog R, Regeur L: Neuropharmacology of tics. Rev Neurol (Paris) 1986, 142:856–859.

    CAS  Google Scholar 

  48. Lipinski JF, Sallee FR, Jackson C, Sethuraman G: Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997, 12:402–407.

    Article  PubMed  CAS  Google Scholar 

  49. Gilbert DL, Sethuraman G, Sine L, et al.: Tourette syndrome improvement with pergolide in a randomized, double-blind crossover trial. Neurology, 2000, 54:1310–1315.

    PubMed  CAS  Google Scholar 

  50. Goetz CG, Stebbins GT, Thelen JA: Talipexole and adult Gilles de la Tourette’s syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 1994, 9:315–317.

    Article  PubMed  CAS  Google Scholar 

  51. Dursun SM, Kutcher S: Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Med Hypothesis 1999, 52:101–109.

    Article  CAS  Google Scholar 

  52. Sandberg PR, Fogelson HM, Manderscheid PZ, et al.: Nicotine gum and haloperidol in Tourette syndrome [letter]. Lancet 1988, 1:592.

    Article  Google Scholar 

  53. Sanberg PR, McConville BJ, Fogelson HM, et al.: Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 1989, 43:19–23.

    Article  PubMed  CAS  Google Scholar 

  54. Dursun SM, Reveley MA: Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette’s syndrome: an open study. Psychol Med 1997, 27:483–487.

    Article  PubMed  CAS  Google Scholar 

  55. Sanberg PR, Silver AA, Shytle RD, et al.: Nicotine for the treatment of Tourette’s syndrome. Pharmacol Ther 1997, 74:21–25.

    Article  PubMed  CAS  Google Scholar 

  56. Silver AA, Shytle RD, Sanberg PR: Mecamylamine in Tourette’s syndrome: a two-year retrospective case study. J Child Adolesc Psychopharmacol 2000, 10:59–68.

    PubMed  CAS  Google Scholar 

  57. Hoopes SP: Donepezil for Tourette’s disorder and ADHD. J Clin Psychopharmacol 1999, 19:381–382.

    Article  PubMed  CAS  Google Scholar 

  58. Muller-Vahl KR, Kolbe H, Schneider U, Emrich HM: Cannabinoids: possible role in pathophysiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 1998, 98:502–506.

    PubMed  CAS  Google Scholar 

  59. Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM: Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 1999, 156:495.

    PubMed  CAS  Google Scholar 

  60. Cath DC, Gijsman HJ, Schoemaker RC, et al.: The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology (Berlin) 1999, 144:137–143.

    Article  CAS  Google Scholar 

  61. Bonnier C, Nassogne MC, Evrard P: Ketanserin treatment of Tourette’s syndrome in children. Am J Psychiatry 1999, 156:1122–1123.

    PubMed  CAS  Google Scholar 

  62. Toren P, Laor N, Cohen DJ, et al.: Ondansetron treatment in patients with Tourette’s syndrome. Int Clin Psychopharmacol 1999, 14:373–376.

    Article  PubMed  CAS  Google Scholar 

  63. Scahill L, Riddle MA, King RA, et al.: Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997, 7:75–85.

    PubMed  CAS  Google Scholar 

  64. Bajo S, Battaglia M, Pegna C, Bellodi L: Citalopram and fluvoxamine in Tourette’s disorder. J Am Acad Child Adolesc Psychiatry 1999, 38:230–231.

    Article  PubMed  CAS  Google Scholar 

  65. Sandyk R, Bamford CR, Laguna J: Clomiphene citrate in Tourette’s syndrome [letter]. Postgrad Med J 1987, 63:510–511.

    Article  PubMed  CAS  Google Scholar 

  66. Peterson BS, Zhang H, Anderson GM, Leckman JF: A doubleblind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998, 18:324–331.

    Article  PubMed  CAS  Google Scholar 

  67. Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190–1193.

    Article  PubMed  CAS  Google Scholar 

  68. Marras C, Sime EA, Andrews DF, Lang AE: Botulinum toxin injections for simple motor tics: a randomized, placebo-controlled trial. Neurology 2000, 54(suppl 3):A49.

    Google Scholar 

  69. Trimble MR, Whurr R, Brookes G, et al.: Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998, 13:617–619.

    Article  PubMed  CAS  Google Scholar 

  70. Scott BL, Jankovic J, Donovan DT: Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 1996, 11:431–433.

    Article  PubMed  CAS  Google Scholar 

  71. Swedo SE, Leonard HL, Garvey M, et al.: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections PANDAS. A clinical description of the first fifty cases. Am J Psychiatry 1998, 155:264–271.

    PubMed  CAS  Google Scholar 

  72. Kurlan R: Tourette’s syndrome and ‘PANDAS’; will the relation bear out? Neurology 1998, 50:1530–1534.

    PubMed  CAS  Google Scholar 

  73. Garvey MA, Perlmutter SJ, Allen AJ, et al.: A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry 1999, 45:1564–1571.

    Article  PubMed  CAS  Google Scholar 

  74. Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153–1158.

    Article  PubMed  CAS  Google Scholar 

  75. Rauch SL, Baer L, Cosgrove GR, Jenike MA: Neurosurgical treatment of Tourette’s syndrome: a critical review. Compr Psychiatry 1995, 36:141–156.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neurology and Pediatrics, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Harvey 811, 21287-8811, Baltimore, MD, USA

    Harvey S. Singer MD

Authors
  1. Harvey S. Singer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singer, H.S. The treatment of tics. Curr Neurol Neurosci Rep 1, 195–202 (2001). https://doi.org/10.1007/s11910-001-0016-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-001-0016-8

Keywords

Search

Navigation